Lonza launched a media development lab at its Singapore site to support bioprocessing clients in optimizing their media formulations and facilitating a transition to GMP manufacturing.
As development timelines accelerate and process complexity increases, the cost and risk associated with late-stage reformulation and scaleup continue to rise. Many organizations still lack structured media optimization and alignment between development and manufacturing, according to Lonza.
To address these challenges, the media development lab provides a systematic approach to early media optimization while accounting for scalability, raw material readiness, and GMP manufacturability, notes a company official, who adds that Lonza’s leveraging design of experiments service evaluates multiple variables simultaneously to identify key performance drivers with the goal of accelerating development timelines and reducing unnecessary iterations.
“We are committed to providing customers with the services they need to reduce early-stage risk and select media formulations that are effective at a laboratory scale and simultaneously practical and reliable in manufacturing,” says Michael Goetter, head of bioscience, specialized modalities.
